SHANGHAI – Canbridge Life Sciences Inc., of Beijing, is on its way to bridging the gap that leaves many patients in China waiting anywhere from four years to six years for critical treatments approved in developed markets. With time of the essence, the firm is taking a portfolio approach to its in-licensing strategy, developing both clinical-stage and approved treatments, while mixing new drugs with treatments classified as medical devices. Read More
HONG KONG – A leading Indian biosimilars maker reported a slight decline in biopharma sales in the quarter ending June 30, affected by the chaotic situation in the Middle East. Read More
NEW DELHI – The first budget of India's newly elected government included some nice surprises for India's biotechnology sector in the form of international collab-orations and a new bioclusters initiative. Read More
HONG KONG – A multidisciplinary research team from Singapore has made a significant breakthrough in the understanding of the molecular basis of benign fibroadenomas, one of the most common breast tumors in women, which could have important implications for the diagnosis and treatment of malignant breast cancers. Read More
TOKYO – Two Japanese pharma companies are investing tens of millions into a new biotech venture fund created by Remiges Biopharma Fund LP as they look for new collaborations outside Japan. Read More
TOKYO – A hepatitis C drug in the market in Japan since 2011 has been associated with 15 deaths in a little more than two years and with severe side effects in more than 2,500 patients, according to reports that surfaced over the weekend. Read More
HONG KONG – Leading Chinese vaccine maker Sinovac Biotech Ltd. (NASDAQ:SVA) has emerged as the sole supplier of hepatitis A vaccine in prefilled syringe dosages for the city of Beijing. Read More
Retrophin Inc., of New York, said it submitted a proposal to the board of Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, to acquire by scheme of arrangement all of the shares of Clinuvel stock that Retrophin does not own for 0.175 Retrophin shares per Clinuvel share, or A$2.17 (US$2.04) per share in cash. Read More
